Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis.
J Wilborn, … , R Strieter, M Peters-Golden
J Wilborn, … , R Strieter, M Peters-Golden
Published April 15, 1996
Citation Information: J Clin Invest. 1996;97(8):1827-1836. https://doi.org/10.1172/JCI118612.
View: Text | PDF
Research Article Article has an altmetric score of 3

Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis.

  • Text
  • PDF
Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disorder characterized by inflammation, fibroblast proliferation, and accumulation of extracellular matrix proteins. Leukotrienes (LTs) are pro-inflammatory and pro-fibrogenic mediators derived from the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism. They are thought to play a role in a number of disease processes, but have received relatively little attention in investigations into the pathogenesis of IPF. In this study, we measured the levels of immunoreactive LTs B(4) and C(4) in homogenates of lung tissue obtained from patients with newly diagnosed, untreated IPF, as compared to levels measured in homogenates of uninvolved nonfibrotic lung tissue from patients undergoing resectional surgery for bronchogenic carcinoma. Compared to homogenates on nonfibrotic control lung, homogenates from IPF patients contained 15-fold more LTB(4) and 5-fold more LTC(4). IPF homogenate levels of LTB(4) were significantly correlated with histologic indices of both inflammation (r=0.861) and fibrosis (r=0.926). Activation of 5-LO is known from in vitro studies to be associated with localization of the enzyme at the nuclear membrane. Immunohistochemical staining for 5-LO protein in alveolar macrophages (AMs) demonstrated that such an "activated" localization pattern was significantly more frequent in IPF lung (19.2+/-3.3% of cells) than in control lung (9.3+/-0.9%); this localization pattern was rarely seen (3.2%) in sections from a truly normal transplant donor lung. Consistent with these data, AMs obtained from IPF patients by bronchoalveolar lavage, purified by adherence, and cultured in the absence of a stimulus for 16 h elaborated significantly greater amounts of LTB(4) and LTC(4) than did control AMs obtained from normal volunteers. These data indicate that the 5-LO pathway is constitutively activated in the lungs of patients with IPF, and the AM represents at least one cellular source of LT overproduction in this disorder. We speculate that LTs participate in the pathogenesis of IPF, and their overproduction in this disorder may be amenable to specific pharmacotherapy.

Authors

J Wilborn, M Bailie, M Coffey, M Burdick, R Strieter, M Peters-Golden

×

Total citations by year

Year: 2023 2022 2021 2020 2019 2018 2017 2016 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1985 Total
Citations: 1 2 3 6 7 6 7 3 3 4 3 7 8 6 2 8 10 13 11 10 6 5 4 5 7 2 1 1 151
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (151)

Title and authors Publication Year
Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy.
Chen R, Dai J
Journal of Molecular Medicine 2023
The Dynamic Contribution of Neutrophils in the Chronic Respiratory Diseases
Ham J, Kim J, Ko YG, Kim HY
Allergy, asthma & immunology research 2022
Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis
Williams KM, Pavletic SZ, Lee SJ, Martin PJ, Farthing DE, Hakim FT, Rose J, Manning-Geist BL, Gea-Banacloche JC, Comis LE, Cowen EW, Justus DG, Baird K, Cheng GS, Avila D, Steinberg SM, Mitchell SA, Gress RE
2022
Blocking 5-LO pathway alleviates renal fibrosis by inhibiting the epithelial-mesenchymal transition
J Zhou, R Li, Q Liu, J Zhang, H Huang, C Huang, G Zhang, Y Zhao, T Wu, Q Tang, Y Huang, Z Zhang, Y Li, J He
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2021
Chondroitin sulfate in tissue remodeling: Therapeutic implications for pulmonary fibrosis
Y Kai, H Yoneyama, M Yoshikawa, H Kimura, S Muro
Respiratory Investigation 2021
The role of lipid-based signalling in wound healing and senescence
V Pils, L Terlecki-Zaniewicz, M Schosserer, J Grillari, I Lämmermann
Mechanisms of Ageing and Development 2021
Design and synthesis of Leukotriene A4 hydrolase inhibitors to alleviate idiopathic pulmonary fibrosis and acute lung injury
X Li, M Xie, C Lu, J Mao, Y Cao, Y Yang, Y Wei, X Liu, S Cao, Y Song, J Peng, Y Zhou, Q Jiang, G Lin, S Qin, M Qi, M Hou, X Liu, H Zhou, G Yang, C Yang
European Journal of Medicinal Chemistry 2020
Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways
V Suryadevara, R Ramchandran, DW Kamp, V Natarajan
International journal of molecular sciences 2020
The role of the LTB4-BLT1 axis in health and disease
R He, Chen, Q Cai
Pharmacological research : the official journal of the Italian Pharmacological Society 2020
Phosphorylation of 5-LOX: The Potential Set-point of Inflammation
Z He, D Tao, J Xiong, F Lou, J Zhang, J Chen, W Dai, J Sun, Y Wang
Neurochemical Research 2020
Exercise Improves Lung Inflammation, but Not Lung Remodeling and Mechanics in a Model of Bleomycin-Induced Lung Fibrosis
E El-Mafarjeh, GH Martins, JJ Probst, A Santos-Dias, MC Oliveira-Junior, MP de Barros, LV de Oliveira, LD de Andrade, RK da Palma, R Moraes-Ferreira, D de Camargo Hizume-Kunzler, AL Bachi, RP Vieira, G gory Durand
Oxidative Medicine & Cellular Longevity 2020
Tannic acid alleviates experimental pulmonary fibrosis in mice by inhibiting inflammatory response and fibrotic process
N Rajasekar, A Sivanantham, A Kar, SK Mahapatra, R Ahirwar, RK Thimmulappa, SG Paramasivam, R Subbiah
Inflammopharmacology 2020
Secretion of leukotrienes by senescent lung fibroblasts promotes pulmonary fibrosis
Christopher D Wiley, Alexis Brumwell, Sonnet S Davis, Julia Jackson, Alexis Valdovinos, Cheresa Calhoun, Fatouma Alimirah, Carlos A. Castellanos, Richard Ruan, Ying Wei, Harold Chapman, Arvind Ramanathan, Judith Campisi, Claude Jourdan Le Saux
JCI Insight 2019
Targeting metabolic dysregulation for fibrosis therapy
X Zhao, JY Kwan, K Yip, PP Liu, FF Liu
Nature Reviews Drug Discovery 2019
Role of the high-affinity leukotriene B4 receptor signaling in fibrosis after unilateral ureteral obstruction in mice
M Kamata, H Amano, Y Ito, T Fujita, F Otaka, K Hosono, K Kamata, Y Takeuchi, T Yokomizo, T Shimizu, M Majima, JC Dussaule
PloS one 2019
Lipids - two sides of the same coin in lung fibrosis
A Mamazhakypov, RT Schermuly, L Schaefer, M Wygrecka
Cellular Signalling 2019
Novel drug targets in idiopathic pulmonary fibrosis
M Calvello, MC Flore, L Richeldi
Expert Opinion on Orphan Drugs 2019
Eicosanoids in carcinogenesis
BL Brücher, IS Jamall, OR Bandapalli
2019
AK106-001616, a Potent and Selective Inhibitor of Cytosolic Phospholipase A 2 : In Vivo Efficacy for Inflammation, Neuropathic Pain, and Pulmonary Fibrosis
H Shimizu, A Ito, K Sakurada, J Nakamura, K Tanaka, M Komatsu, M Takeda, K Saito, Y Endo, T Kozaki, M Shoda, H Kuriyama
The Journal of pharmacology and experimental therapeutics 2019
Therapeutic targets and early stage clinical trials for pulmonary fibrosis
S Sato, T Yanagihara, MR Kolb
Expert Opinion on Investigational Drugs 2018
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis
S Aryal, SD Nathan
Expert Opinion on Emerging Drugs 2018
Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis
G Pasciuto, R Inchingolo, C Condoluci, D Magnini, B Iovene, L Richeldi
Current Pulmonology Reports 2018
Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide
KC Meyer, SD Nathan
2018
Tepoxalin a dual 5-LOX-COX inhibitor and erlotinib an EGFR inhibitor halts progression of gastric cancer in tumor xenograft mice
Xinyang Lu, Lunhua Huang, Wei Zhang, Xiaofei Ning
American journal of translational research 2018
Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin-induced pulmonary fibrosis
N Topaloğlu
Turkish Journal of Thoracic and Cardiovascular Surgery 2018
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis
W Lu, X Yao, P Ouyang, N Dong, D Wu, X Jiang, Z Wu, C Zhang, Z Xu, Y Tang, S Zou, M Liu, J Li, M Zeng, P Lin, F Cheng, J Huang
Journal of Medicinal Chemistry 2017
Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite score
E Karatzas, MM Bourdakou, G Kolios, GM Spyrou
Scientific Reports 2017
New treatment directions for IPF: current status of ongoing and upcoming clinical trials
F Macagno, F Varone, PM Leone, PV Mari, L Panico, L Berardini, L Richeldi
Expert Review of Respiratory Medicine 2017
Investigational drugs for idiopathic pulmonary fibrosis
F Varone, G Montemurro, F Macagno, M Calvello, E Conte, E Intini, B Iovene, PM Leone, PV Mari, L Richeldi
Expert Opinion on Investigational Drugs 2017
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?
R Inchingolo, C Condoluci, A Smargiassi, A Mastrobattista, C Boccabella, A Comes, N Golfi, L Richeldi
Expert Opinion on Pharmacotherapy 2017
Therapeutic targets in idiopathic pulmonary fibrosis
M Kolb, F Bonella, L Wollin
Respiratory Medicine 2017
BLT1 Mediates Bleomycin-Induced Lung Fibrosis Independently of Neutrophils and CD4 + T Cells
J Lv, Y Xiong, W Li, W Yang, L Zhao, R He
Journal of immunology (Baltimore, Md. : 1950) 2017
Leukotrienes in exhaled breath condensate and fractional exhaled nitric oxide in workers exposed to TiO 2 nanoparticles
D Pelclova, V Zdimal, P Kacer, Z Fenclova, S Vlckova, M Komarc, T Navratil, J Schwarz, N Zikova, O Makes, K Syslova, J Belacek, S Zakharov
Journal of Breath Research 2016
Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation
KM Williams, GS Cheng, I Pusic, M Jagasia, L Burns, VT Ho, J Pidala, J Palmer, L Johnston, S Mayer, JW Chien, DA Jacobsohn, SZ Pavletic, PJ Martin, BE Storer, Y Inamoto, X Chai, ME Flowers, SJ Lee
Biology of Blood and Marrow Transplantation 2016
How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation
KM Williams
Blood 2016
Paracrine functions of fibrocytes to promote lung fibrosis
KR Kleaveland, BB Moore, KK Kim
Expert Review of Respiratory Medicine 2014
Following the Path of CCL2 from Prostaglandins to Periostin in Lung Fibrosis
BB Moore
American journal of respiratory cell and molecular biology 2014
Emerging therapeutic interventions for idiopathic pulmonary fibrosis
S Chakraborty, P Chopra, SV Ambi, SG Dastidar, A Ray
Expert Opinion on Investigational Drugs 2014
Targeted therapies for systemic sclerosis
CP Denton, VH Ong
Nature Reviews Rheumatology 2013
Leukotriene C 4 aggravates bleomycin-induced pulmonary fibrosis in mice: LTC 4 aggravates pulmonary fibrosis
H Hirata, M Arima, Y Fukushima, K Sugiyama, T Tokuhisa, T Fukuda
Respirology 2013
5-Lipoxygenase mRNA and Protein Isoforms
MJ Ochs, B Suess, D Steinhilber
Basic & Clinical Pharmacology & Toxicology 2013
Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection
R Wisastra, PA Kok, N Eleftheriadis, MP Baumgartner, CJ Camacho, HJ Haisma, FJ Dekker
Bioorganic & Medicinal Chemistry 2013
Pranlukast, a Cysteinyl Leukotriene Type 1 Receptor Antagonist, Attenuates the Progression but Not the Onset of Silica-Induced Pulmonary Fibrosis in Mice
C Shimbori, N Shiota, H Okunishi
International Archives of Allergy and Immunology 2012
Modulatory Effects of Curcumin and Green Tea Extract against Experimentally Induced Pulmonary Fibrosis: A Comparison with N -Acetyl Cysteine: MODULATION OF PULMONARY FIBROSIS
MA Hamdy, SA El-Maraghy, MA el Kortam
Journal of Biochemical and Molecular Toxicology 2012
Leukotrienes B4, C4, D4 and E4 in the Exhaled Breath Condensate (EBC), Blood and Urine in Patients with Pneumoconiosis
D PELCLOV^|^Aacute;, Z FENCLOV^|^Aacute;, S VLCKOV^|^Aacute;, J LEBEDOV^|^Aacute;, K SYSLOV^|^Aacute;, O PECHA, J BEL^|^Aacute;CEK, T NAVR^|^Aacute;TIL, M KUZMA, P KACER
Industrial Health 2012
Prostaglandin E2 and the Pathogenesis of Pulmonary Fibrosis
PD Bozyk, BB Moore
American journal of respiratory cell and molecular biology 2011
Integrating mechanisms of pulmonary fibrosis
TA Wynn
Journal of Experimental Medicine 2011
Novel therapeutic approaches for pulmonary fibrosis
A Datta, CJ Scotton, RC Chambers
British Journal of Pharmacology 2011
Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD
GC Hildebrandt, T Fazekas, A Lawitschka, H Bertz, H Greinix, J Halter, SZ Pavletic, E Holler, D Wolff
Bone Marrow Transplantation 2011
An Official American Thoracic Society Workshop Report: Features and Measurements of Experimental Acute Lung Injury in Animals
G Matute-Bello, G Downey, BB Moore, SD Groshong, MA Matthay, AS Slutsky, WM Kuebler
American journal of respiratory cell and molecular biology 2011
Preventing and managing bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation
JW Chien
Expert Review of Respiratory Medicine 2011
Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice
C Shimbori, N Shiota, H Okunishi
European Journal of Pharmacology 2011
Investigational approaches to therapies for idiopathic pulmonary fibrosis
RH Gomer, ML Lupher
Expert Opinion on Investigational Drugs 2010
Viral infection and aging as cofactors for the development of pulmonary fibrosis
PK Naik, BB Moore
Expert Review of Respiratory Medicine 2010
Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients
BC Norman, DA Jacobsohn, KM Williams, BK Au, MA Au, SJ Lee, CK Moravec, JW Chien
Bone Marrow Transplantation 2010
Retinoic acids exhibit anti-fibrotic activity through the inhibition of 5-lipoxygenase expression in scleroderma fibroblasts
R XIAO, N YOSHIDA, Y HIGASHI, QJ LU, T FUKUSHIGE, T KANZAKI, T KANEKURA
The Journal of Dermatology 2010
Leukotriene B4, administered via intracerebroventricular injection, attenuates the antigen-induced asthmatic response in sensitized guinea pigs
YL Zhu, SJ Zhang, YM Deng, XW Dong, JX Jiang, QM Xie
Journal of Neuroinflammation 2010
Effect of inhaled KP-496, a novel dual antagonist of the cysteinyl leukotriene and thromboxane A2 receptors, on a bleomycin-induced pulmonary fibrosis model in mice
S Kurokawa, M Suda, T Okuda, Y Miyake, Y Matsumura, M Ishimura, R Saito, T Nakamura
Pulmonary Pharmacology & Therapeutics 2010
Splanchnic Hypoperfusion Provokes Acute Lung Injury via a 5-Lipoxygenase Dependent Mechanism
EE Moore
The American Journal of Surgery 2010
Involvement of leukotrienes in the pathogenesis of silica-induced pulmonary fibrosis in mice
C Shimbori, N Shiota, H Okunishi
Experimental Lung Research 2010
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009
Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation - An Increasingly Recognized Manifestation of Chronic Graft-versus-Host Disease
JW Chien, S Duncan, KM Williams, SZ Pavletic
Biology of Blood and Marrow Transplantation 2009
Determinants of initiation and progression of idiopathic pulmonary fibrosis
RM KOTTMANN, CM HOGAN, RP PHIPPS, PJ SIME
Respirology 2009
Latent herpesvirus infection augments experimental pulmonary fibrosis
KM Vannella, TR Luckhardt, CA Wilke, LF van Dyk, GB Toews, BB Moore
American journal of respiratory and critical care medicine 2009
Bronchiolitis Obliterans After Allogeneic Hematopoietic Stem Cell Transplantation
KM Williams
Journal of the American Medical Association 2009
Inflammation and cancer: how friendly is the relationship for cancer patients?
BB Aggarwal, P Gehlot
Current Opinion in Pharmacology 2009
Viruses as co-factors for the initiation or exacerbation of lung fibrosis
KM Vannella, BB Moore
Fibrogenesis & Tissue Repair 2008
Eicosanoid Lipid Mediators in Fibrotic Lung Diseases
SK Huang, M Peters-Golden
Chest 2008
Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease—insights and potential therapeutic implications
O Kowal-Bielecka, K Kowal, O Distler, S Gay
Nature Clinical Practice Rheumatology 2007
Current and emerging drugs for idiopathic pulmonary fibrosis
M Gharaee-Kermani, B Hu, VJ Thannickal, SH Phan, MR Gyetko
Expert Opinion on Emerging Drugs 2007
Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids
P Rubin, KW Mollison
Prostaglandins & Other Lipid Mediators 2007
Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice
T Izumo, M Kondo, A Nagai
Life Sciences 2007
Cysteinyl Leukotrienes Are Autocrine and Paracrine Regulators of Fibrocyte Function1
KM Vannella, TR McMillan, RP Charbeneau, CA Wilke, PE Thomas, GB Toews, M Peters-Golden, BB Moore
Journal of immunology (Baltimore, Md. : 1950) 2007
The histone deacetylase inhibitor trichostatin A mediates upregulation of 5-lipoxygenase promoter activity by recruitment of Sp1 to distinct GC-boxes
N Schnur, S Seuter, C Katryniok, O Rådmark, D Steinhilber
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2007
8-isoprostane and Leukotrienes in Exhaled Breath Condensate in Czech Subjects with Silicosis
D PELCLOVÁ, Z FENCLOVÁ, P KAČER, T NAVRÁTIL, M KUZMA, J LEBEDOVÁ, P KLUSÁČKOVÁ
Industrial Health 2007
Cysteinyl Leukotrienes Are Autocrine and Paracrine Regulators of Fibrocyte Function
KM Vannella, TR McMillan, RP Charbeneau, CA Wilke, PE Thomas, GB Toews, M Peters-Golden, BB Moore
Journal of immunology (Baltimore, Md. : 1950) 2007
Epithelial-mesenchymal interactions in pulmonary fibrosis
JC Horowitz, VJ Thannickal
Seminars in respiratory and critical care medicine 2006
Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury
M Failla, T Genovese, E Mazzon, E Gili, C Muià, M Sortino, N Crimi, AP Caputi, S Cuzzocrea, C Vancheri
Respiratory Research 2006
Idiopathic Pulmonary Fibrosis
JC Horowitz, VJ Thannickal
Treatments in Respiratory Medicine 2006
Opposing roles of leukotrienes and prostaglandins in fibrotic lung disease
BB Moore, M Peters-Golden
Expert Review of Clinical Immunology 2006
Expression of 5-lipoxygenase in specialized epithelial cells of nasopharyngeal-associated lymphoid tissue
TG Brock
Journal Of Molecular Histology 2006
Cysteinyl Leukotriene Levels in Esophageal Mucosal Biopsies of Children with Eosinophilic Inflammation: Are They All the Same?
SK Gupta, M Peters-Golden, JF Fitzgerald, JM Croffie, MD Pfefferkorn, JP Molleston, MR Corkins, JR Lim
The American Journal of Gastroenterology 2006
Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy
JC Horowitz, VJ Thannickal
Treatments in Respiratory Medicine 2006
Idiopathic Pulmonary Fibrosis: New Concepts in Pathogenesis and Implications for Drug Therapy
JC Horowitz, VJ Thannickal
Treatments in Respiratory Medicine 2006
Hepcidin expression and iron transport in alveolar macrophages
NB Nguyen, KD Callaghan, AJ Ghio, DJ Haile, F Yang
American journal of physiology. Lung cellular and molecular physiology 2006
Role of 5-Lipoxygenase in IL-13-Induced Pulmonary Inflammation and Remodeling
YM Shim, Z Zhu, T Zheng, CG Lee, RJ Homer, B Ma, JA Elias
Journal of immunology (Baltimore, Md. : 1950) 2006
TNF-alpha sensitizes normal and fibrotic human lung fibroblasts to Fas-induced apoptosis
SK Frankel, GP Cosgrove, SI Cha, CD Cool, MW Wynes, BL Edelman, KK Brown, DW Riches
American journal of respiratory cell and molecular biology 2005
Regulating leukotriene synthesis: The role of nuclear 5-lipoxygenase
TG Brock
Journal of Cellular Biochemistry 2005
Molecular mechanisms underlying inflammatory lung diseases in the elderly: Development of a novel therapeutic strategy for acute lung injury and pulmonary fibrosis
T Nagase, T Aoki-Nagase, Y Yamaguchi, H Yamamoto, Y Ouchi
Geriatrics and Gerontology International 2005
Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: An imbalance between proinflammatory and antiinflammatory lipid mediators
O Kowal-Bielecka, K Kowal, O Distler, J Rojewska, A Bodzenta-Lukaszyk, BA Michel, RE Gay, S Gay, S Sierakowski
Arthritis & Rheumatism 2005
Emerging drugs for idiopathic pulmonary fibrosis
VJ Thannickal, KR Flaherty, RC Hyzy, JP 3rd
Expert Opinion on Emerging Drugs 2005
Traitements médicamenteux de la fibrose pulmonaire idiopathique
B Crestani, S Marchand-Adam, S Schneider
Revue de Pneumologie Clinique 2005
Group IB secretory phospholipase A2 stimulates leukotriene B4 production by a unique mechanism in human neutrophils
HY Lee, MK Kim, KS Park, EH Shin, YS Bae
Biochemical and Biophysical Research Communications 2005
Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis
I Stelmach, A Korzeniewska, W Stelmach, P Majak, T Grzelewski, J Jerzynska
Annals of Allergy Asthma & Immunology 2005
Fibrosis pulmonar idiopática: en busca de un tratamiento eficaz
M Selman, C Navarro, M Gaxiola
Archivos de Bronconeumología 2005
Involvement of cAMP-response element binding protein-1 in arachidonic acid-induced vascular smooth muscle cell motility
N Dronadula, F Rizvi, E Blaskova, Q Li, GN Rao
Journal of lipid research 2005
Nuclear localization of leukotriene A 4 hydrolase in type II alveolar epithelial cells in normal and fibrotic lung
TG Brock, YJ Lee, E Maydanski, TL Marburger, M Luo, R Paine, M Peters-Golden
American journal of physiology. Lung cellular and molecular physiology 2005
Phosphorylation by Protein Kinase A Inhibits Nuclear Import of 5-Lipoxygenase
M Luo, SM Jones, N Flamand, DM Aronoff, M Peters-Golden, TG Brock
The Journal of biological chemistry 2005
Toward functional proteomics of alveolar macrophages
HM Wu, M Jin, CB Marsh
American journal of physiology. Lung cellular and molecular physiology 2005
Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis
TC Beller, DS Friend, A Maekawa, BK Lam, KF Austen, Y Kanaoka
Proceedings of the National Academy of Sciences 2004
Mechanisms of Pulmonary Fibrosis
VJ Thannickal, GB Toews, ES White, JP Lynch, FJ Martinez
Annual Review of Medicine 2004
Cysteinyl leukotrienes: biosynthesis and receptors
B Lam, Y Kanaoka, J Boyce, KF Austen
Clinical & Experimental Allergy Reviews 2004
Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy
VJ Thannickal, KR Flaherty, FJ Martinez, JP 3rd
Expert Opinion on Pharmacotherapy 2004
Five-lipoxygenase-activating protein inhibitor MK-886 induces apoptosis in gastric cancer through upregulation of p27kip1and bax
XM Fan, SP Tu, SK Lam, WP Wang, J Wu, WM Wong, MF Yuen, MC Lin, HF Kung, BC Wong
Journal of Gastroenterology and Hepatology 2004
Montelukast and airway remodeling in children with chronic persistent asthma: an open study
M Pifferi, D Caramella, V Ragazzo, ED Marco, A Pietrobelli, AL Boner
Pediatric Allergy and Immunology 2004
Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects
KK Brown, G Raghu
Clinics in Chest Medicine 2004
Characterization of Interleukin-4–Stimulated Nasal Polyp Fibroblasts
JW Steinke, CD Crouse, D Bradley, K Hise, K Lynch, SE Kountakis, L Borish
American journal of respiratory cell and molecular biology 2004
Idiopathic Pulmonary Fibrosis: Pathogenesis and Therapeutic Approaches
M Selman, VJ Thannickal, A Pardo, DA Zisman, FJ Martinez, JP Lynch
Drugs 2004
Effect of Montelukast, a Cysteinyl Receptor Antagonist, on Myofibroblasts in Interstitial Lung Disease
E Fireman, Y Schwartz, A Mann, J Greif
Journal of Clinical Immunology 2004
Disorders of lung matrix remodeling.
Chapman HA
Journal of Clinical Investigation 2004
NOVELPHARMACOLOGICALAPPROACHES TOMANAGEINTERSTITIALLUNGFIBROSIS IN THETWENTY-FIRSTCENTURY
SN Giri
Annual Review of Pharmacology and Toxicology 2003
Leukotriene C4 synthase
BK Lam
Prostaglandins, Leukotrienes and Essential Fatty Acids 2003
5-Lipoxygenase and FLAP
M Peters-Golden, TG Brock
Prostaglandins, Leukotrienes and Essential Fatty Acids 2003
The plasmin system in airway remodeling
I Kucharewicz, K Kowal, W Buczko, A Bodzenta-Łukaszyk
Thrombosis Research 2003
N OVEL P HARMACOLOGICAL A PPROACHES TO M ANAGE I NTERSTITIAL L UNG F IBROSIS IN THE T WENTY -F IRST C ENTURY
SN Giri
Annual Review of Pharmacology and Toxicology 2003
Lung Biology in Health and Disease
N Zamel
Lung Biology in Health and Disease: Experimental Models and Therapeutic Potential 2003
Lung Biology in Health and Disease: Potential Mediators and Therapeutic Targets in Fibrotic Lung Disease
M Peters-Golden
Lung Biology in Health and Disease: Experimental Models and Therapeutic Potential 2003
Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling
Stephen T Holgate, Marc Peters-Golden, Reynold A Panettieri, William R Henderson Jr
Journal of Allergy and Clinical Immunology 2003
Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease
O Kowal-Bielecka, O Distler, K Kowal, Z Siergiejko, J Chwieko, A Sulik, RE Gay, AB ukaszyk, S Gay, S Sierakowski
Arthritis & Rheumatism 2003
Rheumatoid arthritis and leukotriene receptor
A Hashimoto, S Kono, H Endo, H Kondo
Ensho Saisei 2003
A Role for Cysteinyl Leukotrienes in Airway Remodeling in a Mouse Asthma Model
WR Henderson, LO Tang, SJ Chu, SM Tsao, GK Chiang, F Jones, M Jonas, C Pae, H Wang, EY Chi
American journal of respiratory and critical care medicine 2002
A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis
T Nagase, N Uozumi, S Ishii, Y Kita, H Yamamoto, E Ohga, Y Ouchi, T Shimizu
Nature Medicine 2002
Future Research Directions in Idiopathic Pulmonary Fibrosis: Summary of a National Heart, Lung, and Blood Institute Working Group
RG Crystal, PB Bitterman, B Mossman, MI Schwarz, D Sheppard, L Almasy, HA Chapman, SL Friedman, TE King, LA Leinwand, L Liotta, GR Martin, DA Schwartz, GS Schultz, CR Wagner, RA Musson
American journal of respiratory and critical care medicine 2002
The 5-Lipoxygenase Pathway: A New Therapeutic Target for the Treatment of Pulmonary Fibrosis
DC Zeldin
American journal of respiratory and critical care medicine 2002
Protection from Pulmonary Fibrosis in Leukotriene-Deficient Mice
M Peters-Golden, M Bailie, T Marshall, C Wilke, SH Phan, GB Toews, BB Moore
American journal of respiratory and critical care medicine 2002
Oxidant-mediated increases in redox factor-1 nuclear protein and activator protein-1 DNA binding in asbestos-treated macrophages
DM Flaherty, MM Monick, AB Carter, MW Peterson, GW Hunninghake
Journal of immunology (Baltimore, Md. : 1950) 2002
Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice
CB Keerthisingam, RG Jenkins, NK Harrison, NA Hernandez-Rodriguez, H Booth, GJ Laurent, SL Hart, ML Foster, RJ McAnulty
The American Journal of Pathology 2001
Potential role of leukotrienes in other disease states
M Peters-Golden
Clinical & Experimental Allergy Reviews 2001
Origins and treatment of airway inflammation in childhood asthma
RF Lemanske
Pediatric Pulmonology 2001
Inflammation
JA Hunt
Encyclopedia of Materials Science and Technology 2001
GM-CSF Increases AP-1 DNA Binding and Ref-1 Amounts in Human Alveolar Macrophages
DM Flaherty, MM Monick, AB Carter, MW Peterson, GW Hunninghake
American journal of respiratory cell and molecular biology 2001
Intracellular Compartmentalization of Leukotriene Biosynthesis
M Peters-Golden, TG Brock
American journal of respiratory and critical care medicine 2000
Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes
MJ Cameron, GA Arreaza, M Grattan, C Meagher, S Sharif, MD Burdick, RM Strieter, DN Cook, TL Delovitch
Journal of immunology (Baltimore, Md. : 1950) 2000
Prolonged Exposure to Lipopolysaccharide Inhibits Macrophage 5-Lipoxygenase Metabolism Via Induction of Nitric Oxide Synthesis
MJ Coffey, SM Phare, M Peters-Golden
Journal of immunology (Baltimore, Md. : 1950) 2000
In Situ Amplification of 5-Lipoxygenase and 5-Lipoxygenase-Activating Protein in Allergic Airway Inflammation and Inhibition by Leukotriene Blockade
SJ Chu, LO Tang, E Watney, EY Chi, WR Henderson
Journal of immunology (Baltimore, Md. : 1950) 2000
Pulmonary diseases other than asthma as potential targets for antileukotriene therapy
M Peters-Golden
Clinical Reviews in Allergy & Immunology 1999
The Biology of 5-Lipoxygenase: Function, Structure, and Regulatory Mechanisms
ES Silverman, JM Drazen
Proceedings of The Association of American Physicians 1999
Pharmacological Therapy for Idiopathic Pulmonary Fibrosis: Past, Present, and Future
RJ Mason, MI Schwarz, GW Hunninghake, RA Musson
American journal of respiratory and critical care medicine 1999
Immunoglobulins and Cellular Constituents of the BAL Fluid of Patients With Sulfur Mustard Gas-Induced Pulmonary Fibrosis
A Emad, GR Rezaian
Chest 1999
Novel Inhibitors of Leukotrienes
G Folco, B Samuelsson, RC Murphy
1999
Molecular mechanisms of leukotriene synthesis: the changing paradigm
Peters-Golden
Clinical & Experimental Allergy 1998
Collagenase-3 induction in rat lung fibroblasts requires the combined effects of tumor necrosis factor-alpha and 12-lipoxygenase metabolites: a model of macrophage-induced, fibroblast-driven extracellular matrix remodeling during inflammatory lung injury
TJ Mariani, S Sandefur, JD Roby, RA Pierce
Molecular biology of the cell 1998
Capacity for repeatable leukotriene generation after transient stimulation of mast cells and macrophages
TG Brock, RW McNish, M Peters-Golden
Biochemical Journal 1998
Role of leukotrienes in antimicrobial defense of the lung
M Peters-Golden, M Coffey
Journal of Laboratory and Clinical Medicine 1998
5-Lipoxygenase and 5-Lipoxygenase Activating Protein (FLAP) Immunoreactivity in Lungs from Patients with Primary Pulmonary Hypertension
L Wright, RM Tuder, J Wang, CD Cool, RA Lepley, NF Voelkel
American journal of respiratory and critical care medicine 1998
Cell Biology of the 5-Lipoxygenase Pathway
M Peters-Golden
American journal of respiratory and critical care medicine 1998
Altered expression and localization of 5-lipoxygenase accompany macrophage differentiation in the lung
RB Covin, TG Brock, MB Bailie, M Peters-Golden
American journal of physiology. Lung cellular and molecular physiology 1998
γ-linolenic acid-containing diet attenuates bleomycin-induced lung fibrosis in hamsters
VA Ziboh, M Yun, DM Hyde, SN Giri
Lipids 1997
Rapid Import of Cytosolic 5-Lipoxygenase into the Nucleus of Neutrophils after in Vivo Recruitment and in Vitro Adherence
TG Brock, RW McNish, MB Bailie, M Peters-Golden
The Journal of biological chemistry 1997
The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice
CD Funk
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1996
Leukotrienes
J Ophir, S Brenner, S Kivity
International Journal of Dermatology 1985

← Previous 1 2 3 … 6 7 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
51 readers on Mendeley
See more details